Saturday 17 October 2026
Export HOWL’s income statement to Excel — free account
Werewolf Therapeutics, Inc.
HOWL Healthcare Biotechnology
Werewolf Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $1.9 million, down 90.5% from fiscal 2023. In the quarter to June 2026, revenue grew 256.1%, EPS grew 120.0% and free cash flow grew 146.5%, each against the same quarter a year earlier.
0.98
0.02
−2.00%
Follow HOWL
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | — | — | — |
+8 more quarters Free account |
P/S ratio |
0.72 | — | — | — | |
P/FCF ratio |
0.00 | — | — | — | |
P/Operating CF |
2.64 | — | — | — | |
P/B ratio |
1.07 | — | — | — | |
Price to Tangible BV |
1.07 | — | — | — | |
EV/Sales |
0.70 | — | — | — | |
EV/EBITDA |
0.00 | — | — | — | |
EV/Operating CF |
(0.57) | — | — | — | |
EV/FCF |
(0.57) | — | — | — | |
Quick Ratio |
2.80 | 1.21 | 1.58 | 3.73 | |
Current Ratio |
2.91 | 1.27 | 1.62 | 3.87 | |
Net Debt/EBITDA |
(2.29) | 3.61 | 6.33 | 2.87 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 27.20% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.73 | |
Asset Turnover |
0.42 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.81 | 0.78 | 1.32 | 0.93 | |
Capex/Depreciation |
0.17 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
15.07 | (9.70) | (6.88) | (11.73) | |
Research and Development Expense of Revenue |
29.34% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
36.57% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
2.00% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
0.86 | — | — | — | |
Graham Number |
0.00 | — | — | — | |
Earnings Yield |
(202.78%) | — | — | — | |
Free Cash Flow Yield |
(170.76%) | — | — | — | |
Revenue per Share |
0.43 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
0.14 | (0.22) | (0.24) | (0.33) | |
Capex per Share |
0.01 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.15 | (0.22) | (0.24) | (0.33) | |
Cash per Share |
0.45 | 0.96 | 1.24 | 1.43 | |
Shareholders Equity per Share |
0.34 | 0.25 | 0.54 | 0.65 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.34 | 0.25 | 0.54 | 0.65 | |
Free Cash Flow |
7.05 | (10.60) | (11.02) | (15.16) | |
Working Capital |
15.03 | 10.22 | 22.44 | 50.57 | |
Capital Expenditures |
0.42 | — | — | — | |
Net Current Asset Value |
15.03 | 2.91 | 14.00 | 18.16 | |
EV/EBIT |
0.00 | — | — | — | |
Capex to Sales |
(0.02) | — | — | — | |
Price to Operating Income |
0.00 | — | — | — | |
| Other line items | |||||
Average Payables |
2.36 | 2.28 | 1.89 | 1.16 | |
Average Assets |
58.36 | 82.63 | 98.16 | 109.83 | |
Average Common Equity |
28.88 | 34.75 | 49.10 | 59.50 |
Columns are period end dates